Abstract
Pancreatic cancer is projected to become the second most common cause of cancer death over the next 5 years. Since inflammation is thought to be a common trajectory for disease initiation, we sought to prospectively characterize immune profiles using DNA methylation markers to examine whether they play a key role in pancreatic cancer risk. In a nested case-control study pooling three U.S. prospective cohort studies, DNA methylation was measured in prediagnostic leukocytes of incident pancreatic cancer cases and matched controls using the Illumina MethylationEPIC array. Differentially methylated regions were used to predict immune cell types and CpGs previously associated with blood inflammatory markers were selected for the analysis. DNA methylation data from a retrospective case-control study conducted in Spain (PanGenEU) was used for independent replication of results. Immune cell proportions and ratio of cell proportions were not associated with pancreatic cancer risk in the nested case-control study. Methylation extent of CpGs residing in or near gene MNDA was significantly associated with pancreatic cancer risk in the nested case-control study and replicated in PanGenEU. In the nested case-control study, the associations were present 10 or more years prior to cancer diagnosis. Methylation of a promoter CpG of gene PIM-1 was associated with pancreatic cancer survival in both studies. We identified several CpGs that may play a role in pancreatic carcinogenesis using a targeted approach for the selection of inflammation-based CpGs in two large, independent studies conducted in different countries with distinct study designs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research reported in this publication was primarily supported by the NIH/National Cancer Institute grant R01 CA207110. In addition, other NIH funds contributed to the support of the investigators: R01 CA163451, and P30 CA168525, and the Kansas IDeA Network of Biomedical Research Excellence Bioinformatics Core, supported in part by the National Institute of General Medical Science (NIGMS) Award P20GM103418. The PanGenEU study was funded by: Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI11/01542, #PI0902102, #PI12/01635, #PI12/00815, #PI15/01573); European Cooperation in Science and Technology – COST Action #BM1204; EUPancreas EU-6FP Integrated Project (#018771-MOLDIAG-PACA), EU-FP7-HEALTH (#259737-CANCERALIA, #256974-EPC-TM-Net).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Support: The research reported in this publication was primarily supported by the NIH/National Cancer Institute grant R01 CA207110. In addition, other NIH funds contributed to the support of the investigators: R01 CA163451, and P30 CA168525, and the Kansas IDeA Network of Biomedical Research Excellence Bioinformatics Core, supported in part by the National Institute of General Medical Science (NIGMS) Award P20GM103418.
The PanGenEU study was funded by: Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI11/01542, #PI0902102, #PI12/01635, #PI12/00815, #PI15/01573); European Cooperation in Science and Technology – COST Action #BM1204; EUPancreas EU-6FP Integrated Project (#018771-MOLDIAG-PACA), EU-FP7-HEALTH (#259737-CANCERALIA, #256974-EPC-TM- Net).
↵1 Principal Investigator in each center
Data Availability
All data from this study have been deposited in dbGAP and will be available on January 3, 2020 [“DNA Methylation Markers and Pancreatic Cancer Risk in 3 Cohort Studies (NHS, PHS, HPFS)” phs001917.v1.p1].
https://www.ncbi.nlm.nih.gov/projects/gapprev/gap/cgi-bin/study.cgi?study_id=phs001917.v1.p1
